Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Editorial] CAR T-cells: an exciting frontier in cancer therapy

On Aug 30, the US Food and Drug Administration (FDA) approved tisagenlecleucel (marketed by Novartis as Kymriah) as the first ever treatment that genetically modifies patients’ own T cells. The approval is for children and young adults (up to 25 years of age) with relapsed or refractory acute B-cell lymphoblastic leukaemia—a leading cause of childhood cancer deaths. This treatment option is currently limited to 20 specially certified centres in the USA because of the complexity of the procedure and potentially serious side-effects.

email